Revenue, 2025

USD 254.65 Billion

Forecast, 2035

USD 594.07 Billion

CAGR, 2026-2035

8.84%

Report Coverage

Global

Pharmaceutical CRO and CDMO Market Trends for 2026

The global pharmaceutical CRO and CDMO market size was estimated at USD 254.65 billion in 2025 and is predicted to increase from USD 277.16 billion in 2026 to approximately USD 594.07 billion by 2035, expanding at a CAGR of 8.84% from 2026 to 2035.

The growing development of various advanced treatment options is increasing the demand for pharmaceutical CRO and CDMO services, leading to their collaborations. Furthermore, their growing expansion and adoption of advanced technologies are also promoting the market growth.

Key Takeaways

• Pharmaceutical CRO and CDMO market to crossed USD 277.16 billion by 2026.
• Market projected at USD 594.07 billion by 2035.
• CAGR of 8.84% expected in between 2026 to 2035.
• North America dominated the global pharmaceutical CRO and CDMO market by 40% share in 2025.
• Asia Pacific is expected to be the fastest-growing region between 2026 and 2035.
• By CRO type, the clinical research services (CRO) segment dominated the market with the share of 34% in 2025.
• By CRO type, the clinical data management (CRO) segment is expected to be the fastest growing during the forecast period.
• By CDMO type, the API development and manufacturing (CDMO) segment dominated the market by 30% share in 2025.
• By CDMO type, the drug product manufacturing (CDMO) segment is expected to be the fastest-growing during the forecast period.
• By therapy area type, the oncology segment dominated the market by 36% share in 2025.
• By therapy area type, the infectious diseases segment is expected to be the fastest growing during the forecast period.

What are the Pharmaceutical CRO and CDMO?

The pharmaceutical CRO and CDMO market is driven by the growing shift towards asset light business model to manage the increasing R&D cost and technical complexities. The pharmaceutical CRO and CDMO encompasses the companies providing outsourced research, drug development, and manufacturing services. They offer various drug development, drug testing, and clinical trial services.

Strategic Outsourcing and Biopharma Innovation Are Transforming the Pharmaceutical CRO and CDMO Market

Pharmaceutical Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs) provide outsourced services for drug discovery, preclinical and clinical research, formulation development, manufacturing, analytical testing, and regulatory support, enabling pharmaceutical and biotechnology companies to accelerate product development. The pharmaceutical CRO and CDMO market is expanding due to increasing outsourcing by drug developers, rising demand for biologics and specialty medicines, and the need to reduce development costs and accelerate time-to-market. Key trends include integrated end-to-end service offerings, decentralized clinical trials, and growing partnerships between biotech firms and service providers. Technological advancements such as AI-driven drug discovery, continuous manufacturing, digital quality management, and advanced bioprocessing technologies are improving operational efficiency. Future opportunities lie in cell and gene therapies, personalized medicine, emerging biopharmaceutical markets, and expanding investments in advanced manufacturing infrastructure.

Government Initiatives

• In January 2026, the EU Pharmaceutical Legislation Reform entered its implementation phase, modernizing the pharmaceutical regulatory framework and supporting innovation, clinical research, and advanced manufacturing.
• In May 2026, the Critical Medicines Act reached a provisional agreement to strengthen pharmaceutical manufacturing capacity, improve medicine supply chains, and reduce dependency on external suppliers, creating new opportunities for CROs and CDMOs.

Internal and External Factors Affecting the Pharmaceutical CRO and CDMO Market

The pharmaceutical CRO and CDMO market is influenced by several internal factors, including manufacturing capacity, technical expertise, regulatory compliance, quality assurance systems, operational efficiency, skilled workforce availability, digital transformation, production scalability, and investments in advanced manufacturing technologies. External factors include increasing pharmaceutical and biotechnology outsourcing, rising demand for biologics, biosimilars, and cell and gene therapies, evolving global regulatory requirements, patent expirations, supply chain disruptions, geopolitical developments, foreign direct investments, expanding healthcare expenditure, and growing pharmaceutical R&D activities. Strategic collaborations, mergers and acquisitions, sustainability initiatives, and increasing demand for cost-effective drug development and manufacturing services further strengthen long-term market growth.

What is the Use of AI in the Market?

AI offers a wide range of applications, which are increasing its use in the pharmaceutical CRO and CDMO market, where it is being utilized to enhance drug development, clinical trials, patient recruitment, and their optimization. It helps in data management, quality control, and inventory management. It is also used in the identification of drug safety profiles, accelerating their development with reduced errors and failures.

What are the Trends & Future Outlook of the Market?

Growth in Outsourcing Trends

There is a rise in the outsourcing trends, which is increasing the partnerships with the pharmaceutical CRO and CDMO, for affordable and specialised services, and reducing the clinical trials and product development timelines.

Increasing Development of Complex Therapeutics

To deal with the growing chronic and complex diseases, the companies are focusing on the development of various complex therapeutics, promoting collaboration with the pharmaceutical CRO and CDMOs.

Expanding Decentralized Trials

The growing digitalization is increasing the use of various remote monitoring and telemedicine platforms, which is increasing the adoption of decentralized clinical trials and hybrid trials.

Rising Outsourcing Trends Accelerating Pharmaceutical CRO and CDMO Market Growth

Increasingly, pharmaceutical & biotechnology companies are partnering with organizations (CRO/CDMOs), who have proven capabilities in their respective areas to reduce costs, provide access to new & advanced capabilities, and provide institutional regulatory & quality support, which ultimately will lead to faster and more efficient development and production of pharmaceutical products. In addition, both growing investments in biologics, cell & gene therapy, and personalized medicine are creating increasingly more opportunities for outsourcing as well.

In addition to this growth of available products for outsourcing, the number of clinical trials being conducted, the increasing cost associated with meeting compliance with regulations, and expanding production capacity of pharmaceuticals in emerging markets are all contributing positively to the overall growth of the CRO and CDMO pharmaceutical market. Strategic alliances and long-term outsourcing contracts will continue to provide the opportunity for additional operational efficiencies, as well as for providing innovation opportunities throughout the pharmaceutical value chain.

Quick Facts Table

Segmental Insights

By CRO Insights

Explanation

• Clinical Research Services manage human trials and hold 34% and dominate due to high demand in drug development and regulatory approvals.
• Preclinical Research Services support early-stage testing and hold 18% but do not dominate as they precede clinical phases.
• Clinical Data Management handles trial data processing and holds 16% and is the fastest-growing segment due to rising data complexity and digitalization.
• Bioanalytical Testing Services analyze biological samples and hold 14% but do not dominate as they serve a supporting role.
• Clinical Trial Logistics & Supply Chain Management ensures trial material flow and holds 18% but does not dominate due to its operational support function.

Why Did the Clinical Research Services (CRO) Segment Dominate in the Market in 2025?

The clinical research services (CRO) segment held the largest share of 34% in the pharmaceutical CRO and CDMO market in 2025, due to growth in the outsourcing trends. Moreover, the complex, stringent, and lengthy clinical trials also increase their demand. Additionally, growth in the development of advanced technologies also increased their use.

Clinical Data Management (CRO)

The clinical data management (CRO) segment is expected to show the highest growth during the upcoming years, due to growing clinical trials. Furthermore, the growing decentralized and hybrid trials are also increasing their demand for maintaining data integrity and traceability by integrating advanced technologies.

By CDMO Insights

Explanation

• API Development & Manufacturing produces active pharmaceutical ingredients and holds 30% and dominates due to its critical role in drug production.
• Formulation Development designs drug delivery systems and holds 18% but does not dominate as it is an intermediate stage.
• Drug Product Manufacturing converts formulations into final dosage forms and holds 22% and is the fastest-growing segment due to rising demand for finished drugs.
• Packaging & Labeling Services ensure product safety and compliance and hold 12% but do not dominate as they are end-stage processes.
• Analytical & QC Testing Services maintain quality and regulatory standards and hold 18% but do not dominate as they serve a supporting validation role.

How API Development and Manufacturing (CDMO) Segment Dominated the Market in 2025?

The API development and manufacturing (CDMO) segment led the pharmaceutical CRO and CDMO market with the share of 30% in 2025, as they are essential for the development of various products. The growth in the development of small molecule-based products also increased their demand. Moreover, to reduce the regulatory burden also increased their use.

Drug Product Manufacturing (CDMO)

The drug product manufacturing (CDMO) segment is expected to show the fastest growth during the predicted time, due to the growing use of biologics. This is driving their development, increasing the collaboration with CDMO for these services. Additionally, their improved high-quality facilities are also encouraging their use.

By Therapy Area Insights

Explanation

• Oncology focuses on cancer treatment and holds 36% and dominates due to high disease burden and strong R&D investment.
• Cardiovascular Diseases address heart-related conditions and hold 20% but do not dominate due to diverse treatment approaches.
• Infectious Diseases target bacterial and viral infections and hold 18% and are the fastest-growing segment due to emerging pathogens and global health focus.
• Musculoskeletal Disorders manage bone and joint conditions and hold 10% but do not dominate due to moderate demand.
• Others include various therapeutic areas and hold 16% but do not dominate due to fragmented applications.

Which Therapy Area Type Segment Held the Dominating Share of the Market in 2025?

The oncology segment held the dominating share in the pharmaceutical CRO and CDMO market with 36% share in 2025, due to growth in drug development. The lengthy trials and their complexities also increased the partnerships with pharmaceutical CRO and CDMOs. Furthermore, the growing outsourcing trends have also increased their demand.

Infectious Diseases

The infectious diseases segment is expected to show the highest growth during the predicted time, due to growing incidences of infectious diseases. The growing government support and increasing immunization campaigns are also increasing the development of various treatment option driving the demand for pharmaceutical CRO and CDMO services.

Regional Insights

Well-Developed Industries Drive North America

North America dominated the pharmaceutical CRO and CDMO market in 2025, due to the presence of advanced industries and enhanced R&D investments. The presence of stringent regulations and skilled personnel also increased the dependence on the pharmaceutical CRO and CDMOs for product development and clinical trials, which contributed to the market growth.

U.S. Market Trends

The growing R&D investments in the U.S. are increasing the outsourcing trends, leading to an increasing use of pharmaceutical CRO and CDMO services. The advanced clinical trial infrastructure, regulatory expertise, and skilled personnel are also increasing their use to accelerate drug development, clinical trials, and product approvals.

Canada Market Trends

The pharmaceutical contract research organization (CRO) and contract development and manufacturing organization (CDMO) industry is continuing to expand throughout Canada due largely to the ongoing growth of biopharmaceutical research, the rise in clinical trial activity, and the demand for outsourced drug development and manufacturing services. Continued growth will be aided by regulatory standards and a continued focus on innovation within the life sciences industry.

Mexico Market Trends

The pharmaceutical CRO and CDMO market in Mexico is continuing to grow steadily due to the availability of low-cost manufacturing, the continued expansion of the pharmaceutical manufacturing sector, and a continuing increase in the activity of clinical research. Continued investment by global pharmaceutical companies in Mexico is also reinforcing Mexico's position as an outsourcing destination.

Large Patient Population Boosts Asia Pacific

Asia Pacific is expected to host the fastest-growing pharmaceutical CRO and CDMO market during the forecast period, due to the diverse patient population. The expanding industries are also leading to the launch of new pharmaceutical CRO and CDMOs. Furthermore, the growing government support, stringent regulations, and investments are also enhancing the market growth.

China Market Trends

The expanding industries in China are increasing the development of biologics, cell & gene therapies, vaccines, etc, which is growing the demand for pharmaceutical CRO and CDMO services. The growing diseases and manufacturing services are also increasing their use, where the increasing government initiatives are also promoting their collaborations.

Japan Market Trends

The pharmaceutical CRO and CDMO market in Japan is supported by a well-developed pharmaceutical sector, solid research capabilities, and a growing demand for outsourcing complex drug development initiatives. Additional support for the market is coming from an increased focus on biologics, precision medicine, and drug development innovation.

India Market Trends

India is experiencing rapid growth in the pharmaceutical CRO and CDMO industry due to its large pool of educated and skilled workers, cost-effective manufacturing capabilities, and the presence of a robust generic pharmaceuticals industry. The momentum behind the industry's expansion is due to growth in biologics production, rising levels of clinical trial activity, and increasing investments in advanced drug development services.

Europe Driven by Stringent Regulations

Europe is expected to grow significantly in the pharmaceutical CRO and CDMO market during the forecast period, due to the presence of a stringent regulatory framework. The presence of advanced industries is also increasing the development of various products, leading to new collaborations with the pharmaceutical CRO and CDMOs. The growing R&D activities are also promoting the market growth.

UK Market Trends

The UK consists of well-developed industries, which are collaborating with the pharmaceutical CRO and CDMO to enhance the development and clinical trials of their next-generation products. Their advanced infrastructure and regulatory expertise are also encouraging new strategic partnerships, which are also being supported by government investments.

Germany Market Trends

Germany's pharmaceutical CRO and CDMO market benefits from a well-developed pharmaceutical manufacturing industry, an excellent research environment, and strict regulatory requirements. Increased outsourcing of drug development and commercial production has resulted in continued market growth.

Netherlands Market Trends

The Netherlands has experienced growth in the CRO and CDMO market for pharmaceuticals. This growth is supported by a well-established life sciences sector, logistic services, and high-quality biopharmaceutical research; the demand for custom development and production services continues to aid the market's growth.

Market Ecosystem Analysis

Market Value Chain Analysis

R&D

• The R&D of the pharmaceutical CRO and CDMO focuses on enhancing drug discovery and optimizing their manufacturing using advanced platforms and AI-driven solutions.
• Key players: IQVIA, WuXi AppTec, Lonza.

Clinical Trials and Regulatory Approvals

• The drug safety, quality, efficacy, and manufacturing compliance are evaluated in the clinical trials and regulatory approvals of the pharmaceutical CRO and CDMO.
• Key players: ICON plc, Lonza, Catalent.

Formulation and Final Dosage Preparation

• The formulation and final dosage preparation in the pharmaceutical CRO and CDMO focus on the development of various formulations ranging from oral solids to sterile injectables by optimizing drug stability and delivery mechanisms.
• Key players: Lonza, Catalent, Patheon.

Packaging and Serialization

• The packaging and serialization of pharmaceutical CRO and CDMO products involves the use of tamper-evident designs and unique data track barcodes to maintain product integrity and supply chain traceability.
• Key players: Thermo Fisher Scientific, Catalent, PCI Pharma Services.

Patient Support and Services

• Decentralized trials platform, digital engagement tools, and home nursing are provided in the patient support and services of the pharmaceutical CRO and CDMOs.
• Key players: IQVIA, ICON plc, Parexel.

Market Top Vendors and Their Offerings

Market Share Influence Assessment

Competitive Landscape

SWOT Analysis

Strengths

• The pharmaceutical CRO and CDMO offer clinical expertise, which increases the dependence on them during various clinical trial phases.
• They also offer a well-established trial infrastructure, which promotes faster and more efficient clinical trials.
• The presence of advanced technologies and compliance with regulatory standards also encourages their collaborations.
• Moreover, their affordable and specialized manufacturing capabilities also attract companies.

Weaknesses

• The dependence on sponsor funding acts as the major weakness in the pharmaceutical CRO and CDMO market, which limits the use of their services.
• Lack of skilled personnel increases the risk of product failure, which decreases their collaborations.

Opportunities

• The growing outsourcing trends are driving the demand for pharmaceutical CRO and CDMO services.
• The increasing development of biologics and advanced therapies is also increasing their collaborations.
• Similarly, growing interest in orphan drugs and personalized medication is also increasing their use.
• The expanding decentralized trails are also promoting the use of their services.

Threats

• Limited quality control affects the product quality, development, and manufacturing, decreasing the reliance on pharmaceutical CRO and CDMOs.
• High raw material costs and stringent regulations also slow down the development of the products, limiting their use.

Key Announcements by Industry Players

• In May 2026, Altasciences and Certara entered a strategic partnership to accelerate early-stage drug development by integrating model-informed drug development (MIDD) capabilities into Altasciences’ platform. Marie-Hélène Raigneau, CEO of Altasciences, said, "By embedding Certara’s modeling capabilities into our platform, we can further inform critical decisions earlier and with greater confidence." 
• In June 2026, Ardena appointed Ariane de Ganck, PhD, as Chief Scientific Officer to strengthen scientific leadership and improve coordination across complex drug development programs. Ariane de Ganck said, “Ariane’s track record across scientific, operational, and commercial leadership roles makes her exceptionally well-suited to this position,” said Jeremie Trochu, CEO of Ardena.

Recent Developments in the Market

• In January 2026, a collaboration was formed between ST Pharm, which is a Korean CDMO, and a U.S.-based biotech company, where they will develop an oligonucleotide-based treatment for patients suffering from severe hypertriglyceridemia.
• In March 2025, a 'hybrid' CDMO model was launched by Shilpa Medicare, which is an Indian CDMO at DCAT 2025, where the company will offer traditional CDMO services and ready-to-license novel formulations.

Segments Covered in the Report

By CRO

• Clinical Research Services (CRO)
• Preclinical Research Services (CRO)
• Clinical Data Management (CRO)
• Bioanalytical Testing Services (CRO)
• Clinical Trial Logistics and Supply Chain Management (CRO)

By CDMO

• Formulation Development (CDMO)
• API Development and Manufacturing (CDMO)
• Drug Product Manufacturing (CDMO)
• Packaging and Labeling Services (CDMO)
• Analytical and QC Testing Services (CDMO)

By Therapy Area

• Oncology
• Cardiovascular Diseases
• Infectious Diseases
• Musculoskeletal Disorders
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
  • Rest of North America
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Europe
  • Western Europe
    • Germany
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal
    • Belgium
    • Ireland
    • UK
    • Iceland
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe
    • Austria
    • Russia & Belarus
    • Türkiye
    • Albania
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • Taiwan
  • India
  • Japan
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea
  • Rest of APAC
• MEA
  • GCC Countries
    • Saudi Arabia
    • United Arab Emirates (UAE)
    • Qatar
    • Kuwait
    • Oman
    • Bahrain
  • South Africa
  • Egypt
  • Rest of MEA